Rhoifolin has the potential to be among the effective precursors for the treatment of diabetes and exerts its antidiabetic effects via increased adiponectin secretion, GLUT4 translocation and phosphorylation of insulin receptor-β in 3T3-L1 fat cells, which explains the traditional use of C. grandis in diabetes. The gene discussed is SLC2A4; the disease is diabetes mellitus.